Craneware Faces Revenue Growth Challenges Due to Cyberattack and Regulatory Issues
Healthcare software company Craneware has issued a revised revenue outlook for the year ending June 2027, projecting $185 million in annual recurring revenue. This marks a significant slowdown from previous expectations due to two key issues: an ongoing cyberattack disclosed in July and regulatory uncertainty affecting its U.S. 340B drug-pricing market operations. The company reported flat year-over-year revenue at around $206 million, with adjusted EBITDA rising slightly by 3% to $67.1 million. However, net revenue retention dropped from 107% to 100%, signaling a slowdown in customer spending growth. The cyberattack has led to ongoing legal and regulatory assessments, while the evolving complexity of drug pricing rules is delaying transaction conversions. Craneware's stock fell nearly 24% following these developments as investors grapple with revised expectations for future revenue compounding.
Tickers: $NVDA
Topics: 340B drug-pricing market cyberattack regulatory_changes revenue guidance